Abstract
The last sentence of the article requires further comment: “US breast cancer patients >70 years of age have a higher 5-year survival rate than German patients” (1). The authors mention that systemic treatment is less frequently provided with advancing age. However, this only applies to aggressive chemotherapy, not to antihormonal therapy. Regarding the range of side effects associated with antihormonal treatment, it has to be distinguished between aromatase inhibitors and tamoxifen. The latter directly targets the cancer cell. Its use over a period of 10 years is superior to that over 5 years and results in a better prognosis (2): 21% recurrence rate vs. 25%, and 12% mortality rate vs. 15%, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
